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Purpose of the study
TMC278 is a next-generation investigational NNRTI with
potent and sustained efficacy through 96 weeks in ARV-
naïve patients [1]. The current trial evaluated the PK inter-
action between omeprazole and TMC278. Omeprazole
increases gastric pH, which can affect the solubility and
gastro-intestinal absorption of TMC278. Furthermore,
TMC278 has been shown to induce CYP2C19 in vitro,
which may influence the omeprazole PK.
Methods
This was an open-label, randomized, 2-way crossover trial
in 16 HIV-negative volunteers. In two sessions, separated
by a 14-day washout, participants received TMC278 150
mg QD alone (11 days), and omeprazole 20 mg QD (22
days) with co-administration of TMC278 150 mg QD
(day 12–22). All treatments were taken following break-
fast. Steady-state 24-hr PK profiles of TMC278 were
assessed on the last day of each session and steady-state
24-hr PK profiles of omeprazole and its metabolite 5-
hydroxy(OH)-omeprazole (formed via CYP2C19) were
assessed without (day 11) and with (day 22) co-adminis-
tration of TMC278. PK parameters were calculated using
non-compartmental analysis. The AUC24 h ratio of 5-OH-
omeprazole to omeprazole was used as a surrogate marker
of CYP2C19 activity. Least square (LS) means and associ-
ated 90% CI of treatment ratios (test/reference) were cal-
culated based on log-transformed PK parameters.
When combined with omeprazole, the TMC278 steady-
state AUC24 h decreased by 40% (LS mean ratio 0.60, 90%
CI 0.51–0.71) compared to administration of TMC278
alone, and the steady-state Cmax and Cmin decreased by
40% (0.60, 90% CI 0.48–0.73) and 33% (0.67, 90% CI
0.58–0.78), respectively. TMC278 at steady state
decreased the omeprazole AUC24 h by 14% (0.86, 90%CI
0.76–0.97). Repeated doses of TMC278 resulted in a 27%
increase of the AUC24 h ratio of 5-OH-omeprazole to ome-
prazole (1.27, 90%CI 1.18–1.36). The latter suggests
weak induction of CYP2C19 by TMC278 150 mg QD, an
effect which will likely be less at lower doses, and is
unlikely to result in clinically relevant interactions.
TMC278 alone or in combination with omeprazole was
generally well tolerated. No grade 3 or 4 adverse events
(AEs) and no serious AEs were reported. There were no
discontinuations due to AEs.
Conclusion
These results confirm the pH-dependent bioavailability of
TMC278 and indicate that proton pump inhibitors and
TMC278 25 mg QD (selected dose for Phase III) should
not be co-administered. As an alternative, H2-antagonists
can be used, if taken 12 hours before or 4 hours after
TMC278 [2].
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